Back to search results

Anakinra for Heart Attack Patients to Prevent Heart Failure

This study is testing if the medicine anakinra can help prevent heart failure (weakening of the heart) in people who have recently had a heart attack. Researchers believe that inflammation (the body's reaction to injury) after a heart attack might lead to heart failure. Anakinra is an anti-inflammatory medicine that works by blocking this inflammation. You might be able to join if you've had a specific type of heart attack (ST segment elevation myocardial infarction) within the last 12 hours. The study will look at how well anakinra helps improve your peak oxygen consumption (peak VO2) after 6 weeks. The current recruitment status is unclear, and about 84 people are planned to participate.

Study design
This study is designed to compare anakinra to a placebo (an inactive substance) in approximately 84 participants. Assignment to either anakinra or placebo will be determined randomly, like a coin flip.
What's involved
You would receive daily injections of either anakinra or placebo for up to 14 days. A nurse will give injections while you are in the hospital, and you will be taught to give them at home after discharge. Your participation in the study will last approximately 1 year.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome, peak oxygen consumption, will be measured at 6 weeks. Overall participation in the study will last approximately 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05177822

Interleukin-1 Blockade in Acute Myocardial Infarction to Prevent Heart Failure

Active, Not Recruiting
PHASE2Ages 21+InterventionalPrevention
Virginia Commonwealth University
~84 participants
Updated 2026-05-06 on ClinicalTrials.gov
What's tested:AnakinraPlacebo

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Peak oxygen consumption (peak VO2)
Measured over 6 weeks

Conditions

Heart Failure

Explore related trials

ST-Elevation Myocardial Infarction

Where it's being run

2 sites across 1 states
Virginia2

Study leadership

  • Benjamin Van Tassell, PharmD · PRINCIPAL_INVESTIGATOR · Virginia Commonwealth University

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Acute ST segment elevation myocardial infarction defined as:
chest pain, consistent with angina, within the prior 12 hours (for intermittent pain lasting more than 12 hours, the time from the when the pain became severe and constant);
ST segment elevation on ECG \>1 mm in 2 or more anatomically contiguous leads;
Reperfusion strategy planned or completed (including percutaneous coronary intervention or fibrinolysis)
Age \>21 years.
Failed reperfusion strategy (unsuccessful percutaneous coronary intervention);
Need or plan for emergent cardiac surgery;
Anticipated inability to complete a cardiopulmonary exercise test (CPET) on a treadmill at follow up visit at 42 days (i.e. amputee, wheel-chair bound, severe non-cardiac illness limiting mobility).
Active infection (such as acute, i.e. COVID-19, or chronic/recurrent infectious disease i.e HBV, HCV, and HIV/AIDS-but excluding HCV+ patients with undetectable plasma RNA)
Acute or chronic inflammatory disease or immunosuppressive therapies (including oral corticosteroids at a dose of prednisone equivalent of 0.5 mg/kg/day but not including inhaled or low dose oral corticosteroids or non-steroidal anti-inflammatory drugs).
Neutropenia (\<1,500/mm3 or \<1,000/mm3 in African-American patients).
Active acute or chronic psychiatric illness that in the opinion of the investigator may prevent from complying with study instructions;
Stage V chronic kidney disease (estimated glomerular filtration rate 15 mL/min/1.73m2 or less) or on renal-replacement therapy (a GFR ≥45 mL/min/1.73m2 is required for the cardiac magnetic resonance portion of the study);
Limited English Proficiency that in the opinion of the investigator may prevent from understanding the content of the informed consent form and instructions during the tests required for the study.
Any comorbidity limiting survival or ability to complete the study.

Exclusion

Pregnancy;
Inability to obtain consent from patient;
History of prior STEMI or of systolic heart failure (LVEF\<40%);
Contraindications to treatment with anakinra (i.e. prior allergic reaction to Kineret® or E. coli derived products);

What this trial measures

  • Peak oxygen consumption (peak VO2)6 weeks

    Peak VO2 (expressed as % of predicted) will be assess using cardiopulmonary exercise testing (CPET)